Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:

BioShield Funding: Aventis Prefers Production Deals, Not R&D Support

  • News

Executive Summary

Aventis-Pasteur would prefer a guaranteed manufacturing agreement rather than incremental payments for bioterrorism countermeasures developed under "Project BioShield.

You may also be interested in...



PhRMA Urges Antitrust Exemption For Bioterrorism Research

An antitrust exemption to allow pharmaceutical companies to share production techniques for bioterrorism countermeasures will speed development of necessary agents, the Pharmaceutical Research & Manufacturers of America says

PhRMA Urges Antitrust Exemption For Bioterrorism Research

An antitrust exemption to allow pharmaceutical companies to share production techniques for bioterrorism countermeasures will speed development of necessary agents, the Pharmaceutical Research & Manufacturers of America says

BioShield Should Extend Liability Protection To Unapproved Products – BIO

Liability protections under "Project BioShield" should be extended to companies that make unapproved bioterrorism countermeasures available in an emergency situation, the Biotechnology Industry Organization said

Table

View full table

Tags:
UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By